TY - JOUR T1 - Could nan1-expression and production by pseudomonas aeruginosa be a prognostic factor for survival in CF patients JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA4862 VL - 48 IS - suppl 60 SP - PA4862 AU - Guergana Petrova AU - Penka Perenovska AU - Tanya Strateva Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA4862.abstract N2 - Background:  Neuraminidase production in isolates of  Pseudomonas aeruginosa  from CF patients was described and suggested to contribute to pulmonary infection.Aim: To evaluate nan1 presence in chronically infected with P.aerugenosa CF patients and it's impact on survival and clinical course.Material and methods: In 2008 we evaluated clinical course and state of 29 patients with cystic fibrosis (CF) aged from 7 to 17 years of age, with chronic P. aeruginosa infection. We searched for nan1 among the studied isolates of P. aeruginosa by PCR. Based on nan1 results the patients were divided in two groups – nan1 positive (nan1 (+)) and nan1 negative (nan1(-)). We reevaluated the same patients 7 years later.Results: In 2008 there was no significant difference in sex (p>0.05) or genetic mutation (p>0.05) distribution in both groups. Patients' age also was not significantly different 14.3 ± 3.01 years in nan1(+) group (n=14) and 14.0 ± 3.1 years for nan1 (-) (n=15) (p>0.05). Period of chronic colonization was higher in nan1(+) group 5.6 ± 1.4 years vs. 3 ± 1.4 years (p=0.05) . Nan 1(+) group have more recurrent exacerbations of pulmonary disease and weaker clinical status. In 2015 all but one patient from nan1(+) group have died, while in nan1(-) group only 2 death are registered. In 2015 - four from the alive patients from nan1(-) group in 2008 have nan1(+) P.aeruginosa in their sputum, and are in worse clinical (examination and PFT) state compared to the rest 9 of this group, but similar to the only one survival from nan1(+) group.Conclusion: Chronic pseudomonas infection with strains positive for neuraminidase could be additional prognostic factor for poor prognosis. ER -